Elanco Animal Health Incorporated
ELAN
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $12.2B
$24.50
▲ +0.35%
P/E
-59.76
Mkt Cap
$12.2B
52-Wk Range
$18.22–$27.98
52-Week Range
$18.22 - $27.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 28.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strong brand portfolio with market-leading products recognized globally by veterinarians and consumers
- Integrated manufacturing and distribution network serving multiple customer channels
- Diversified revenue base across companion animals and production agriculture reduces cyclical risk
- Established relationships with veterinary professionals and agricultural producers
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- Significant premium - growth priced in
Growth
Turning profitable
Increasing global pet ownership and spending on pet healthcare
Value
Significant premium - growth priced in
Momentum
Stable
+3.5% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ELAN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.34 vs $0.27 consensus (+26.3% surprise). Revenue of $1.4B vs $1.3B expected (+4.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+26.3%
Revenue trend · last 8Q
—
—
-1%
+5%
+10%
+12%
+15%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.0B
$1.0B
$1.2B
$1.2B
$1.1B
$1.1B
$1.4B
$1.4B
Margins · last 8Q
Gross
58.3%
Operating
18.8%
Profit
4.0%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 6, 2026
vs Industry
How ELAN stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related